Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for Immune Reconstitution in Older Cancer Patients
NCT01339000Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Apr 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant human interleukin-7 in immunosuppression, sponsored by National Cancer Institute. Started Apr 2011; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
immunosuppression
Beyond the preview
Go deeper on NCT01339000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01339000.